3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
81
Colorectal Neoplasms
39
Stomach Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Liver Neoplasms
14
Neoplasms
11
Melanoma
11
Carcinoma, Renal Cell
11
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Transitional Cell
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Ovarian Neoplasms
7
Head and Neck Neoplasms
7
Cholangiocarcinoma
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Merkel Cell
5
Biliary Tract Neoplasms
5
Prostatic Neoplasms
4
Sarcoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Interventions
pembrolizumab
3
Nivolumab
3
Ipilimumab
2
Interleukin-2
2
Drug Therapy
2
Biopsy
2
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
cobimetinib
1
brodalumab
1
atezolizumab
1
Trastuzumab
1
Tissue Banks
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Photochemotherapy
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Mass Screening
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled